Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04197986
Recruitment Status : Recruiting
First Posted : December 13, 2019
Last Update Posted : August 2, 2021
Sponsor:
Collaborator:
Helsinn Healthcare SA
Information provided by (Responsible Party):
QED Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2024
Estimated Study Completion Date : January 31, 2025